Intensive and Critical Care
Anemia Management
Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss. (opens new window)
Source: Crit Care Med 2009;37(4):1299-307.
Indexed: PubMed 19242343
DOI: 10.1097/CCM.0b013e31819cec94
https://www.ncbi.nlm.nih.gov/pubmed/19242343 (opens new window)
Recombinant human erythropoietin therapy in critically ill Jehovah's Witnesses. (opens new window)
Source: Pharmacotherapy 2008;28(11):1383-90.
Indexed: PubMed 18956998
DOI: 10.1592/phco.28.11.1383
https://www.ncbi.nlm.nih.gov/pubmed/18956998 (opens new window)
Reducing postburn injury anemia in a Jehovah's Witness patient. (opens new window)
Source: J Burn Care Res 2014;35(4):e258-61.
Indexed: PubMed 24121804
DOI: 10.1097/BCR.0b013e3182a366c5
https://www.ncbi.nlm.nih.gov/pubmed/24121804 (opens new window)
A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit. (opens new window)
Source: Clin Ther 2008;30(12):2324-34.
Indexed: PubMed 19167591
DOI: 10.1016/j.clinthera.2008.12.024
https://www.ncbi.nlm.nih.gov/pubmed/19167591 (opens new window)
Severe acute anemia after liver transplantation in an elderly Jehovah's Witness treated with high-dose erythropoietin and ferric carboxymaltose: a case report. (opens new window)
Source: Transplant Proc 2015;47(8):2548-51.
Indexed: PubMed 26518969
DOI: 10.1016/j.transproceed.2015.09.014
https://www.ncbi.nlm.nih.gov/pubmed/26518969 (opens new window)
Recombinant human erythropoietin in severe anaemia: issues of dosing and duration. (opens new window)
Source: Anaesth Intensive Care 2006;34(6):793-6.
Indexed: PubMed 17183900
https://www.ncbi.nlm.nih.gov/pubmed/17183900 (opens new window)
Efficacy of recombinant human erythropoietin in the critically ill patient: a randomized, double-blind, placebo-controlled trial. (opens new window)
Source: Crit Care Med 1999;27(11):2346-50.
Indexed: PubMed 10579246
https://www.ncbi.nlm.nih.gov/pubmed/10579246 (opens new window)
Erythropoietin for critically ill trauma patients: a missed opportunity? (opens new window)
Source: J Trauma Acute Care Surg 2014;77(5):774-9.
Indexed: PubMed 25494432
DOI: 10.1097/TA.0000000000000442
https://www.ncbi.nlm.nih.gov/pubmed/25494432 (opens new window)
Postoperative management of severe acute anemia in a Jehovah's Witness. (opens new window)
Source: Transfusion 2014;54(4):1153-7.
Indexed: PubMed 24117834
DOI: 10.1111/trf.12424
https://www.ncbi.nlm.nih.gov/pubmed/24117834 (opens new window)
Restrictive transfusion in geriatric trauma patients. (opens new window)
Source: Am Surg 2016;82(1):85-8.
Indexed: PubMed 26802863
https://www.ncbi.nlm.nih.gov/pubmed/26802863 (opens new window)
High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. (opens new window)
Source: J Trauma 1998;44(2):361-7.
Indexed: PubMed 9498512
DOI: 10.1097/00005373-199802000-00023
https://www.ncbi.nlm.nih.gov/pubmed/9498512 (opens new window)
Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]. (opens new window)
Source: Crit Care 2005;9(5):R508-15.
Indexed: PubMed 16277712
DOI: 10.1186/cc3786
https://www.ncbi.nlm.nih.gov/pubmed/16277712 (opens new window)
Management of a Jehovah's Witness patient with sepsis and profuse bleeding after emergency coronary artery bypass graft surgery: rethinking the critical threshold of oxygen delivery. (opens new window)
Source: A A Case Rep 2015;4(10):127-31.
Indexed: PubMed 25974416
DOI: 10.1213/XAA.0000000000000144
https://www.ncbi.nlm.nih.gov/pubmed/25974416 (opens new window)
Management strategies for perioperative anaemia in the severely burn-injured Jehovah's Witness patients who decline a blood transfusion: a systematic review with illustrative case reports. (opens new window)
Source: Burns. 2023 49(3):716-29. Epub 2022 Jul 18.
Indexed: PubMed 35941026
DOI: 10.1016/j.burns.2022.07.002
https://pubmed.ncbi.nlm.nih.gov/35941026/ (opens new window)
Long-term ECMO treatment in Jehovah's Witness patient without transfusions. (opens new window)
Source: Perfusion 2012;27(4):332-4.
Indexed: PubMed 22496111
DOI: 10.1177/0267659112444328
https://www.ncbi.nlm.nih.gov/pubmed/22496111 (opens new window)
Outcomes with the use of recombinant human erythropoietin in critically ill burn patients. (opens new window)
Source: Am Surg 2010;76(9):951-6.
Indexed: PubMed 20836341
https://www.ncbi.nlm.nih.gov/pubmed/20836341 (opens new window)
Safety of off-label erythropoiesis stimulating agents in critically ill patients: a meta-analysis. (opens new window)
Source: Intensive Care Med 2013;39(11):1896-908.
Indexed: PubMed 23928897
DOI: 10.1007/s00134-013-3030-9
https://www.ncbi.nlm.nih.gov/pubmed/23928897 (opens new window)
Transfusion-free treatment strategies for acute anemia in critical care. (opens new window)
Source: JAAPA 2016;29(8):38-44.
Indexed: PubMed 27467297
DOI: 10.1097/01.JAA.0000488695.96294.33
https://www.ncbi.nlm.nih.gov/pubmed/27467297 (opens new window)
Improved survival of critically ill trauma patients treated with recombinant human erythropoietin. (opens new window)
Source: J Trauma 2008;65(2):285-97.
Indexed: PubMed 18695463
DOI: 10.1097/TA.0b013e31817f2c6e
https://www.ncbi.nlm.nih.gov/pubmed/18695463 (opens new window)
Reticulocyte counts and their relation to hemoglobin levels in trauma patients. (opens new window)
Source: J Trauma 2009;67(1):121-4.
Indexed: PubMed 19590320
DOI: 10.1097/TA.0b013e318187a848
https://www.ncbi.nlm.nih.gov/pubmed/19590320 (opens new window)
Randomized, double-blind, placebo-controlled trial of effects of enteral iron supplementation on anemia and risk of infection during surgical critical illness. (opens new window)
Source: Surg Infect (Larchmt) 2009;10(1):9-19.
Indexed: PubMed 19245362
DOI: 10.1089/sur.2008.043
https://www.ncbi.nlm.nih.gov/pubmed/19245362 (opens new window)
How do we treat life-threatening anemia in a Jehovah's Witness patient? (opens new window)
Source: Transfusion 2014;54(12):3026-34.
Indexed: PubMed 25330835
DOI: 10.1111/trf.12888
https://www.ncbi.nlm.nih.gov/pubmed/25330835 (opens new window)
Recombinant human erythropoietin use in a critically ill Jehovah's Witness after cardiac surgery. (opens new window)
Source: Anesth Analg 2005;101(2):325-7.
Indexed: PubMed 16037136
DOI: 10.1213/01.ANE.0000159158.70532.D0
https://www.ncbi.nlm.nih.gov/pubmed/16037136 (opens new window)
Successful rescue therapy for severe acute anemia: managing the critically ill Jehovah's Witness. (opens new window)
Source: Am Surg 2015;81(6):e263-5.
Indexed: PubMed 26031262
https://www.ncbi.nlm.nih.gov/pubmed/26031262 (opens new window)
Erythropoietin response is blunted in critically ill patients. (opens new window)
Source: Intensive Care Med 1997;23(2):159-62.
Indexed: PubMed 9069000
DOI: 10.1007/s001340050310
https://www.ncbi.nlm.nih.gov/pubmed/9069000 (opens new window)
Life-threatening postoperative blood loss in a Jehovah's Witness, treated with high-dose erythropoietin. (opens new window)
Source: Br J Anaesth 2005;94(4):442-4.
Indexed: PubMed 15653706
DOI: 10.1093/bja/aei068
https://www.ncbi.nlm.nih.gov/pubmed/15653706 (opens new window)
Management of anemia in patients who decline blood transfusion. (opens new window)
Source: Am J Hematol 2018;93(9):1183-91.
Indexed: PubMed 30033541
DOI: 10.1002/ajh.25167
https://pubmed.ncbi.nlm.nih.gov/30033541/ (opens new window)
Erythropoiesis-stimulating agent administration and survival after severe traumatic brain injury: a prospective study. (opens new window)
Source: Arch Surg 2012;147(3):251-5.
Indexed: PubMed 22430906
DOI: 10.1001/archsurg.2011.1838
https://www.ncbi.nlm.nih.gov/pubmed/22430906 (opens new window)
Intravenous iron following cardiac surgery does not increase the infection rate. (opens new window)
Source: Surg Infect (Larchmt) 2006;7(4):361-6.
Indexed: PubMed 16978079
DOI: 10.1089/sur.2006.7.361
https://www.ncbi.nlm.nih.gov/pubmed/16978079 (opens new window)
Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trial. (opens new window)
Source: Crit Care 2015;19:49.
Indexed: PubMed 25888250
DOI: 10.1186/s13054-015-0761-8
https://www.ncbi.nlm.nih.gov/pubmed/25888250 (opens new window)
Pharmacotherapy for reducing RBC transfusion for patients in the ICU: a systematic review and network meta-analysis. (opens new window)
Source: Crit Care Med 2024;52(4):618-25.
Indexed: PubMed 37962159
DOI: 10.1097/CCM.0000000000006114
https://pubmed.ncbi.nlm.nih.gov/37962159/ (opens new window)